Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine and erlotinib

WEN-JIE WANG1*, MENG-YAO WU1*, MENG SHEN1, QIAOMING ZHI2, ZE-YI LIU3,5, FEI-RAN GONG4, MIN TAO1,6,8 and WEI LI1,6

Departments of 1Oncology, 2General Surgery, 3Respiratory Medicine, and 4Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006; 5Institute of Respiratory Diseases, 6PREMED Key Laboratory for Precision Medicine, 7Institute of Medical Biotechnology, Soochow University, Suzhou 215021; 8Jiangsu Institute of Clinical Immunology, Suzhou 215006, P.R. China

Received July 2, 2015; Accepted August 20, 2015

DOI: 10.3892/ijo.2015.3156

Abstract. Increasing evidence suggests that tumors are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth, and are hypothesized to account for therapeutic resistance. Based on the expression of the surface markers CD44, CD24, and EPCAM, putative CSCs have also been identified in pancreatic cancers. It has been well established that aberrant activation of β-catenin signaling pathway may contribute to the maintenance of CSCs. Cantharidin is an active constituent of mylabris, a traditional Chinese medicine. In our previous studies, we demonstrated that cantharidin treatment induced phosphorylation of β-catenin, leading to repression on β-catenin pathway. Therefore, in the present study, we investigated whether cantharidin and its derivant, norcantharidin, could repress the stemness of pancreatic cancer cells through repression on β-catenin pathway. By using microarray and flow cytometry, we found that treatment with cantharidin and norcantharidin repressed the expression of CD44, CD24, and EPCAM at both mRNA and protein levels, leading to decreased CD44+/CD24+/EPCAM+ proportion, the putative pancreatic CSC subset. Pretreatment with the β-catenin pathway inhibitor FH535, attenuated the cantharidin- and norcantharidin-induced repression on CD44, CD24, and EPCAM, suggesting cantharidin and its derivant repressed stemness of pancreatic cancer cells in β-catenin pathway-dependent manner. Furthermore, cantharidin and norcantharidin strengthened the cytotoxicity of gemcitabine and erlotinib, two well established pharmacotherapeutics against pancreatic cancers, indicating cantharidin and norcantharidin could be promising candidates for reversing drug resistance in pancreatic cancers. In conclusion, we presently propose that cantharidin and norcantharidin hold their promise in pancreatic cancer therapy through repression on stemness and strengthening the cytotoxicity of the present therapeutics.

Introduction

Pancreatic cancer is one of the most lethal human cancers. The 1-year survival rate, for all stages of the cancer, is only 26% from the time of diagnosis, and the five-year survival rate is <5% (1). These poor prognoses are mainly attributable to late diagnosis, and its resistance to current therapies. Despite enormous efforts in basic and clinical research in the fight against pancreatic cancer, there is still a huge discrepancy in treatment benefit between preclinical and clinical stages. Even when patients are able to undergo surgery at an early stage, they frequently suffer recurrence or metastasis (2–4). Therefore, new treatments against this aggressive neoplasm are urgently needed.

It has been well accepted that in tumors there is a subgroup of cancer cells, termed cancer stem cells (CSCs) (5). In the past few years, CSCs have been found in most types of hematopoietic and solid tumors including brain tumor, breast, head and neck, colon, lung, prostate, ovarian, and pancreatic cancers (5). CSCs have been proved to preserve the abilities of extensive proliferation, self-renewal, multi-lineage differentiation, and high tumorigenic potential (5). The critical role of pancreatic CSCs in regulating pancreatic cancer progression, metastasis, and drug resistance has since been confirmed (6,7). Therefore,
targeting CSCs could be a novel strategy for the treatment of pancreatic cancers.

Natural products and their derivatives have shown promising outcomes in cancer therapies. In our previous study, we demonstrated that cantharidin, the active constituent of Chinese blister beetle (8), inhibited growth and metastasis of pancreatic cancer cells (9-13), offering a potential role for cantharidin in the treatment of pancreatic cancer. Cantharidin acts as a potent and selective inhibitor of protein phosphatase 2A (PP2A) (14), a multimeric serine/threonine phosphatase. Inhibition of PP2A can result in phosphorylation of multiple substrates, including β-catenin, a key component of WNT/β-catenin pathway. In our previous study, phosphorylation of β-catenin induced by PP2A inhibitors led to repression on WNT/β-catenin pathway (12).

It has been well established that WNT/β-catenin signaling pathway is crucial for normal stem cell self-renewal and tissue differentiation (15). Recent studies proposed that aberrant activation of WNT/β-catenin signaling pathway may contribute to the maintenance of CSCs (16). Therefore, in the present study, we tried to verify whether cantharidin and norcantharidin could repress the stemness of pancreatic cancer cells through inhibition on β-catenin signaling pathway.

As CSCs are generally more resistant than other cancer cells to conventional anticancer therapeutics, we also tried to verify whether cantharidin and norcantharidin could strengthen the cytotoxicity of gemcitabine and erlotinib, two first line pharmacotherapeutics commonly used in the treatment of pancreatic cancers (17).

Materials and methods

Cell line and cultures. The human pancreatic cancer cell lines, PANC-1 and CFPAC-1, were purchased from the United States National Cancer Institute (ATCC, VA, USA). Cells were maintained in Dulbecco's minimum essential medium (DMEM; Gibco, NY, USA) supplemented with 10% fetal calf serum (FCS; Hyclone, UT, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin. The cultures were incubated at 37°C in a humidified atmosphere with 5% CO₂. Cells were passaged every 2-3 days to obtain exponential growth.

Reagents. Cantharidin was purchased from Enzo Life Sciences International (Plymouth Meeting, PA, USA). Norcantharidin (NCTD) was purchased from Sigma (St. Louis, MO, USA). FH355 was purchased from Millipore (Billerica, MA, USA).

MTT assay. Cellular growth was evaluated by MTT (3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyl-tetrazolium bromide) assay (9). Cells were seeded into 24-well tissue culture plates at 5x10³ cells per well. After treatment, MTT (Sigma) was added to each well to a final concentration of 0.5 mg/ml, followed by incubation at 37°C for 4 h. The medium was then removed, and 600 µl of dimethyl sulfoxide (DMSO) was added per well. As the PP2A inhibitor-treated cells became detached (18), the formazan in the medium was harvested by centrifugation at 10,000 rpm for 10 min, dissolved in 200 µl of DMSO, and then returned to the original well. The absorbance of total 800 µl formazan dissolved DMSO in each well was measured at 490 nm using a microplate ELISA reader (Bio-Rad Laboratories, CA, USA). The relative cell viability was calculated as follows: relative cell viability = (mean experimental absorbance/mean control absorbance) x 100%.

Plate clone formation assay. The cells were seeded at a density of 200 cells/well in 24-well plates and treated 12 h later. After 15 days, the cells were stained with 1% methylrosanilinium chloride and the numbers of visible colonies were counted. The relative clone formation ability was calculated as relative clone formation ability = (mean experimental clone number/mean control clone number) x 100%.

Microarray assay. Sample preparation and processing procedure were performed as described in detail in the Agilent GeneChip Expression Analysis Manual (Santa Clara, CA, USA). Differentially expressed genes were screened using Agilent 44K human whole-genome oligonucleotide microarrays. The selection criterion was defined as a >1.5-fold difference in the level of expression (difference in upregulated expression >1.5-fold, and difference in downregulated expression <0.5-fold). Hierarchical clustering of samples was done by average linkage algorithm using TIGR MultiExperiment Viewer (The Institute for Genomic Research, Rockville, MD, USA).

Protein expression evaluation. The protein expression levels of CD24, CD44 and EPCAM in pancreatic cancer cells was measured by flow cytometry. Following treatment, the cells were harvested, fixed with 4% paraformaldehyde and permeabilized using 0.1% Triton X-100. After washing with PBS three times, cells were incubated with anti-CD24 (FITC-conjugated, Santa Cruz), anti-CD44 (PE-conjugated, Santa Cruz), and anti-EPCAM (PerCP-cy5.5-conjugated, Santa Cruz) antibodies, respectively, for 30 min at 4°C. Subsequently, the cells were analyzed using a Beckman Coulter FC500 dual-laser five-color flow cytometer (Beckman Coulter).

Pancreatic cancer cell stemness evaluation. Cells were harvested, washed twice with 2% FBS/PBS solution, and resuspended in 100 µl of 2% FBS/PBS before incubating with anti-CD24 (FITC-conjugated), anti-CD44 (PE-conjugated), and anti-EPCAM (PerCP-cy5.5-conjugated, Santa Cruz) antibodies for 30 min at 4°C. Cells were then washed twice with 2% FBS/PBS solution, and resuspended in 500 µl of 2% FBS/PBS prior to reading on a Beckman Coulter FC500 dual-laser five-color flow cytometer (Beckman Coulter).

Real-time PCR. Total RNA was extracted using TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer's protocol. After spectrophotometric quantification, 1 µg total RNA in a final volume of 20 µl was used for reverse transcription with PrimeScript RT Reagent kit (Takara, Otsu, Shiga, Japan) according to the manufacturer's protocol. Aliquots of cDNA corresponding to equal amounts of RNA were used for quantification of mRNA by real-time PCR using the LightCycler 96 Real-time Quantitative PCR Detection system (Roche, Indianapolis, IN, USA). The reaction system (25 µl) contained the corresponding cDNA, forward and reverse primers, and Sybr Green PCR master mix (Roche). All data were analyzed using B2M gene expression as an internal stan-
The specific primers were as follows: i) CD24, forward, 5'-CAGGGCAATGATGAATGAGAAT-3', reverse, 5'-CCTGGGGCGACAAAGTGAGA-3', product, 233 bp; ii) CD44, forward, 5'-GTGATGGCACCCGCTATGTC-3', reverse, 5'-AACCTCCTGAAGTGCTGCTCC-3', product, 129 bp; iii) EPCAM, forward, 5'-TAATCGTCAATGCCAGTGTACTTC-3', reverse, 5'-GCCATTCATTTCTGCCTTCAT-3', product, 100 bp; iv) B2M, forward, 5'-TCAAGAAGGTGGTGAAGCAG-3', reverse, 5'-AAGGTGGAGGAGTGGGTGTC-3', product, 112 bp.

Statistical analysis. Each experiment was performed a minimum of three times. Results were expressed as the mean value ± standard deviation (SD). Statistical analysis was performed by unpaired Student's t-test. The correlations between microarray assays were analyzed using Spearman's rank correlation analysis. A P-value <0.05 was considered significant.

Results

Cantharidin and norcantharidin repressed pancreatic cancer cell growth and downregulated stemness markers. Dose- and time-dependent repression on pancreatic cancer cell growth by cantharidin and norcantharidin was firstly confirmed by MTT assay (Fig. 1A-D). To investigate the cytotoxicity of long-term exposure of cantharidin and norcantharidin, PANC-1 and CFPAC-1 cells were treated with cantharidin and norcantharidin at low doses and cell growth was evaluated by using plate clone formation assay. As shown in Fig. 1E and F, both cantharidin and norcantharidin presented significant dose-dependent inhibition on the clone formation ability of pancreatic cancer cells. As the clone formation ability often correlated with stemness (19), we further investigated whether cantharidin and norcantharidin could affect the stemness of pancreatic cancer cells. Expressions of stem cell related genes were evaluated by microarray assay. As shown in Fig. 1G,
Figure 2. Cantharidin and norcantharidin repress protein expression of CD24, CD44 and EPCAM. (A and B) Protein expression of CD24 in PANC-1 (A) and CFPAC-1 (B) cells after treatment with cantharidin (CAN) and norcantharidin (NCTD) for 24 h. (C and D) Protein expression of CD44 in PANC-1 (C) and CFPAC-1 (D) cells after treatment with cantharidin (CAN) and norcantharidin (NCTD) for 24 h. (E and F) Protein expression of EPCAM in PANC-1 (E) and CFPAC-1 (F) cells after treatment with cantharidin (CAN) and norcantharidin (NCTD) for 24 h. **P<0.01 indicates significant differences from the respective control groups.

Figure 3. Cantharidin and norcantharidin decreased proportion of pancreatic CSCs. (A) Cantharidin (CAN) and norcantharidin (NCTD) downregulated CD24+/EPCAM+ subset. (B) Cantharidin (CAN) and norcantharidin (NCTD) decreased CD44+/EPCAM+ population. (C) Cantharidin (CAN) and norcantharidin (NCTD) eradicated the CD24+/CD44+ subgroup. (D) Cantharidin (CAN) and norcantharidin (NCTD) abolished CD24+/CD44+/EPCAM+ proportion. **P<0.01 indicates significant differences from the respective control groups.
although 8 genes (EZH2, KLF4, ACVR1, KLF5, CXCR4, ABCB1, ACVR1C and NANOG) were upregulated, expressions of 23 genes (MYC, CD44, CYR61, CD24, SMAD3, SOX9, EPHA2, MYCBP, HMGA2, LGR4, EPCAM, MSX2, MET, NES, ALCAM, HES1, ERBB3, HIF1A, CXCL12, BMI1, ACVR1B, SOX2 and HNF4A) were repressed, suggesting stemness of pancreatic cancer cells was repressed by cantharidin treatment.

Cantharidin and norcantharidin repressed CD24, CD44 and EPCAM expression at protein levels. CD24, CD44 and EPCAM are the well accepted pancreatic CSC markers (20). As microarray assay indicated repressed mRNA expression of these three markers, we further confirmed the downregulation of CD24, CD44 and EPCAM at protein level by using flow cytometry. As shown in Fig. 2, expression of the three markers was downregulated, confirming the repressed stemness of pancreatic cancer cells upon treatment of cantharidin and norcantharidin.

Cantharidin and norcantharidin repress CD24+/CD44+/EPCAM+ proportion in pancreatic cancer cells. As expression of CD24, CD44 and EPCAM was repressed by cantharidin and norcantharidin, we further used flow cytometry to evaluate the positivity of CD24, CD44 and EPCAM on the surface of pancreatic cancer cells. As shown in Fig. 3A-C, flow cytometry by using pairwise coupling of these three markers suggested decreased distributions of all three markers on the surface of pancreatic cancer cells after treatment with cantharidin and norcantharidin. Analysis by using the triplet combination of CD24, CD44 and EPCAM indentified 2.89(±0.37)% and 6.14(±0.47)% CD24+/CD44+/EPCAM+ cells in PANC-1 and CFPAC-1 cells, respectively. After treatment with cantharidin for 24 h, the proportion dropped to 0.07 (±0.03)% and

Figure 4. Cantharidin and norcantharidin repress expression of CD24, CD44 and EPCAM in a β-catenin pathway-dependent manner. (A and B) Pretreatment with FH535 (FH) impaired the repression on CD24 expression by cantharidin (CAN) and norcantharidin (NCTD) in PANC-1 (A) and CFPAC-1 (B) cells. (C and D) Pretreatment with FH535 (FH) impaired the repression on CD44 expression by cantharidin (CAN) and norcantharidin (NCTD) in PANC-1 (C) and CFPAC-1 (D) cells. (E and F) Pretreatment with FH535 (FH) impaired the repression on EPCAM expression by cantharidin (CAN) and norcantharidin (NCTD) in PANC-1 (E) and CFPAC-1 (F) cells. "P<0.05, "P<0.01 vs. respective control groups; "P<0.05, ""P<0.01 vs. FH535 group; "P<0.05, ""P<0.01 induction between groups.
Norcantharidin treatment also resulted in decreased CD24+/CD44+/EPCAM+ population to 0.12(±0.03)% and 0.13(±0.03)% in PANC-1 and CFPAC-1 cells, respectively.

Cantharidin and norcantharidin repress expression of CD24, CD44 and EPCAM β-catenin pathway-dependently. Previous studied indicated that β-catenin pathway is essential for maintaining stemness of CSCs, (16) and we previously demonstrated that cantharidin is able to block the β-catenin pathway (12). To find out whether β-catenin pathway was involved in the repressed stemness by cantharidin and norcantharidin, pancreatic cancer cells were pretreated with the classical β-catenin pathway inhibitor FH535, and expression of CD24, CD44 and EPCAM were then tested after treatment with cantharidin and norcantharidin. As shown in Fig. 4, downregulation of CD24, CD44 and EPCAM was attenuated by FH535 pretreatment in each, suggesting cantharidin and norcantharidin repressed stemness of pancreatic cancer cells β-catenin pathway dependently.

Cantharidin and norcantharidin strengthen cytotoxicity of gemcitabine and erlotinib. Gemcitabine and erlotinib are first line pharmacotherapeutics against pancreatic cancer. However, all patients receive these agents will develop resistance (17). As CSCs are responsible for the relative resistance of the tumor to systemic chemotherapy and radiation (5), and cantharidin and norcantharidin downregulated stemness of pancreatic cancer cells, we then investigate whether cantharidin and norcantharidin could strengthen the cytotoxicity of gemcitabine and erlotinib.

Dose- and time-dependent repression on pancreatic cancer cell growth by gemcitabine and erlotinib was first confirmed by MTT assay (Fig. 5A-D). Then, co-treatment of cantharidin or norcantharidin with gemcitabine or erlotinib was performed. As shown in Fig. 5E and F, co-treatment of cantharidin or norcantharidin with gemcitabine had no synthetic effect. However, cantharidin and norcantharidin significantly strengthened cytotoxicity of erlotinib.

We then performed plate clone formation assay, and evaluated whether cantharidin and norcantharidin could strengthen cytotoxicity of long-term exposure of gemcitabine and erlotinib at low doses. Dose-dependent repression on clone formation ability by gemcitabine and erlotinib was confirmed (Fig. 6A-D). Then, co-treatment of cantharidin or norcantharidin with gemcitabine or erlotinib was performed. As shown in Fig. 6E-H, cantharidin and norcantharidin significantly strengthened cytotoxicity of both gemcitabine and erlotinib, suggesting a potential of combination of cantharidin or norcantharidin with pharmacotherapeutics against pancreatic cancer.

Discussion

Pancreatic cancer is the fourth leading cause of cancer related deaths in Western countries (21). Reasons for the frustrating effort to find effective therapies could be due to the existence of a select population of cancer cells, termed cancer stem cells (CSCs) (5). There is increasing evidence proving that pancreatic cancer is a CSC-driven disease. Isolation and characterization of pancreatic CSCs reveal that these tumor-initiating cells share important molecular pathways seen in other solid-organ cancers.
CSCs (22). The deregulation of the pathway of self-renewal and differentiation in CSCs resulted in unlimited self-renewal and a subsequent excess of CSCs. In addition, CSCs have aberrant differentiation programs that generate progenitor tumor cells, which then proliferate to form the bulk of the tumor (23). CSCs have been found to be resistant to conventional cancer therapies including radiotherapy and chemotherapy. In addition, these cells can also escape the cytotoxic action of the host immune cells (24). Moreover, CSCs show their high propensity of invasiveness and metastasis (5). These features of CSCs could cause cancer recurrence after eliminating most of the cancer cells by conventional therapies. Thus, the presence of CSCs may explain how pancreatic cancer cells can re-grow even when anticancer treatment destroys tumor cells and shrinks the tumor size. Therefore, it is postulated that by developing strategies targeting CSCs can solve the problem of cancer recurrence and metastasis. It is important to note that therapeutics that eliminate the CSCs within a tumor may bring little or no immediate reduction in tumor size. However, tumor growth is not sustainable without CSCs to replenish the bulk population and the tumor will eventually degenerate as bulk tumor cells are depleted. Therefore it is of paramount importance to develop targeted therapies, which eliminate CSC, thereby destroying the sole source for new tumor cells (25).

The first identification of CSCs was reported by Bonnet in acute myeloid leukemia (26). Then, CSCs were identified in

Figure 6. Cantharidin and norcantharidin strengthen cytotoxicity of gemcitabine and erlotinib after long-term exposure. (A and B) Gemcitabine (Gem) (A) and erlotinib (Erl) (B) treatment inhibited the clone formation ability of PANC-1 cells in a dose-dependent manner. (C and D) Gemcitabine (Gem) (C) and erlotinib (Erl) (D) treatment inhibited the clone formation ability of CFPAC-1 cells in a dose-dependent manner. (E and F) PANC-1 cells were co-treated by cantharidin (CAN) or norcantharidin (NCTD) with gemcitabine (Gem) (E) or erlotinib (Erl) (F) for 15 days. (G and H) CFPAC-1 cells were co-treated by cantharidin (CAN) or norcantharidin (NCTD) with gemcitabine (Gem) (G) or erlotinib (Erl) (H) for 15 days. *P<0.01 vs. respective control groups; **P<0.01 vs. cantharidin (CAN) or norcantharidin (NCTD) group; ###P<0.01 induction between groups.
other cancers, including pancreatic cancer (20). Markers that have been utilized to identify pancreatic CSCs include CD24, CD44, EPCAM (a synonym for ESA, which was one of the CSC markers described in the original article of Li et al (20), c-Met (27), CD133 (28), aldehyde dehydrogenase (ALDH) (28), and Hoechst dye exclusion (side population) (29).

CD24 is a heavily glycosylated protein, which was originally described as heat stable B cell-associated antigen. It is thought to be able to facilitate metastasis of tumor cells through binding to P-selectin (30).

CD44 overexpression in tumors has been shown to be correlated with invasiveness, metastasis and poor prognosis in various human tumors (31,32). CD44 participates in cell survival and proliferation by harboring chemokines and growth factors, such as HGF (hepatocyte growth factor). CD44 also plays a role in angiogenesis and invasion via MMP (matrix metalloproteinase) binding (30). CD44 mediates matrix formation, which is crucial for the settlement and growth at a secondary site, whereas apoptosis resistance of CD44 + cells supports the efficacy of metastasis formation (33). Through interaction with integrins such as VLA-4, CD44 is able to activate the MAPK (mitogen-activated protein kinase) pathway. Finally, integrin activation may lead to activation of WNT/β-catenin signaling pathway, which has been proven to be associated with maintaining stemness of CSCs (30,34).

In human pancreatic cancer samples, CD44 expression was correlated with histologic grade and the patients with CD44 + tumors showed poor prognosis (23).

The cell adhesion molecule EPCAM is a type I transmembrane molecule with an EGF (epidermal growth factor)-like domain, followed by a cysteine poor region, a transmembrane domain and a short cytoplasmic tail (36). EPCAM is thought to support metastasis of tumor cells with FH535, a classical β-catenin pathway inhibitor, attenuated the repression on CD44, CD24, and EPCAM by WNT/β-catenin signaling pathway (42).

Combination, but not single marker, has been applied to the identification of pancreatic CSCs. By FACS analysis, Li et al were the first to isolate the CD44+/CD24+/EPCAM + pancreatic CSCs from pancreatic cancer tissue. These CD44+/CD24+/EPCAM + cells showed stem cell properties including self-renewal, the ability to produce differentiated progeny, and the increased expression of sonic hedgehog (20). The CD44+/CD24+/EPCAM + cells had a 100-fold increased tumorigenic potential compared to marker-negative cancer cells. In an animal study, 50% of animals injected with as few as 100 CD44+/CD24+/EPCAM + cells formed tumors that were histologically indistinguishable from the original pancreatic cancer (20). Similar results were shown by follow-up studies. CD44+/CD24 + have a significantly higher possibility for colony formation in vitro (43), and are more resistant to irradiation (43). The characteristics of CD44+/CD24+/EPCAM + cells in clinical specimens of pancreatic cancer using immunohistochemical presented correlation between CD44/CD24/EPCAM expression and poor glandular differentiation as well as high proliferation (44). Survival analysis showed that CD44+/CD24 + expression appeared to be correlated with poor prognosis (44). Thus, investigators have suggested that the subpopulation of pancreatic cancer cells showing CD44+/CD24+/EPCAM + had stem cell-like properties of self-renewal and the ability to produce differentiated progeny (23). In addition, CD44, CD24, and EPCAM are now widely used for the identification of pancreatic cancer stem cells (28,44-47). In the present study, by using CD44, CD24, and EPCAM, we proved that cantharidin and norcantharidin eliminated the stem-like pancreatic cancer cells, making cantharidin and norcantharidin promising candidates for pancreatic cancer treatment.

WNT/β-catenin signaling has a critical role in the regulation of tissue self-renewal, especially in intestinal crypts and bone growth plates (48,49). Deregulated WNT/β-catenin signaling has been associated with CSCs activity; particularly, cutaneous CSCs require β-catenin signaling to maintain their tumorigenic phenotype (34). We previously reported that cantharidin could suppress migration and growth of pancreatic cancer cells via inhibition on the WNT/β-catenin pathway. In the present study, we found that pretreatment of PANC-1 cells with FH535, a classical β-catenin pathway inhibitor, attenuated the repression on CD44, CD24, and EPCAM by cantharidin and norcantharidin, suggesting cantharidin and its derivate suppressed the stemness of pancreatic cancer cells via inhibition on WNT/β-catenin pathway.

Emerging evidence has demonstrated that CSCs are resistant to conventional chemotherapy. It was found that CSCs in mouse mammary tumors contributed to cisplatin resistance (50) and that CSCs in colorectal cancers were responsible for the resistance to chemotherapeutic drugs (51). In chronic myeloid leukemia, imatinib, an Abl tyrosine kinase inhibitor, dramatically depleted differentiated cells but failed to reduce leukaemic stem cells, thus leading to disease progression (23). A previous study using biopsy tissues from patients with breast cancer showed that chemotherapy led to an increased percentage of CD44+/CD24 + cells consistent with increased clone formation ability (52). Liu et al demonstrated that CD133 + cells derived from human glioblastoma were significantly resistant to various chemotherapeutic agents compared to CD133 - cells, and CD133 expression was significantly higher in recurrent glioblastoma (23). Therefore, strategies targeting CSCs are gaining their prospect in cancer treatment.

Similar to other CSCs, the presence of pancreatic CSCs with the drug-resistant and high metastatic characteristics contributes to the treatment failure resulting in high mortality of patients diagnosed with pancreatic cancer. Gemcitabine and erlotinib are first line pharmacotherapeutics commonly used in the treatment of pancreatic cancers (17). However, the median overall survival of gemcitabine treated patients with advanced pancreatic cancer is still only 5-6 months (53). To improve the prognosis of patients, low dose gemcitabine therapy combined with radiotherapy or other chemotherapeutic agents has been used, but with few exceptions, no improvement in the overall survival rates of patients with advanced pancreatic cancer has been reported (54,55). Some EGFR inhibitors (e.g., erlotinib) are approved for lung cancer, however, available data are inconclusive for treatment of pancreatic cancer.
patients with EGFR-targeted therapies (56). This unfavorable situation could be due to the presence of CSCs. Pancreatic CSCs identified by CD133 or CD44/CD24/EPCAM were more resistant to gemcitabine (57,58). In a xenograft model, gemcitabine-treated animals had a decrease in tumor size but an increase in the CD133+ cells fraction (57). Hong et al found that gemcitabine treatment eliminated the bulk of cells but left a CD44+ enriched cells population and a small subset of CD44+/CD24+/EPCAM+ cells, which was able to proliferate and reconstituted the neoplasm (23). Likewise, resistance to erlotinib has also been found to be associated with stemness of pancreatic cancer cells (59).

Therefore, strategies targeting CSCs holds promise in pharmacotherapy sensitization. For example, by using human pancreatic androgenocarcinoma in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice, an in vivo study found that the antitumor effect of gemcitabine was strengthened by XL184, an inhibitor of pancreatic CSC marker c-Met (27). In a separate report, RNA interference of CD44 inhibited the clonogenic activity of gemcitabine-resistant pancreatic cancer cells (23). As cantharidin and norcantharidin were able to eliminate pancreatic CSCs, we investigated whether cantharidin and norcantharidin could strengthen the cytotoxicity of gemcitabine and erlotinib. Although short-term exposure of cantharidin or norcantharidin with gemcitabine did not present synergic effect, data from the long-term co-treatment was favorable. Excitingly, co-treatment of cantharidin or norcantharidin with erlotinib presented synergistic effect after both short- and long-term exposures. Thus, the present study suggested that cantharidin and norcantharidin possess the ability of eliminating pancreatic CSCs, could be promising candidates to strengthen present first line therapeutics against pancreatic cancer.

Because CSCs possess many of the features of normal stem cells, it will be important to determine if such targeting strategies may be effective in tackling CSCs without unduly harming normal stem cells. Two recent reports suggest that selective targeting of CSCs may indeed be possible. A study by Yilmaz and colleagues investigated the role of the tumor suppressor gene PTEN in leukemia (60). They found that conditional deletion of PTEN in adult hematopoietic cells in mice led to expansion of leukemic CSCs and depletion of normal hematopoietic stem cells. Treatment of the mice with rapamycin, used to counter the effects of PTEN deletion, inhibited the development of CSCs while preserving normal stem-cell populations. In another study, targeting the CSC surface molecule CD44 using a monoclonal antibody resulted in eradication of human acute myeloid leukemic stem cells using a xenograft model in immunodeficient mice while sparing normal stem cells (61). Interestingly, it has been proven that clinical treatment with cantharidin and norcantharidin could increase the count of white cells (10), suggesting the stemness repression ability of cantharidin and its derivate could also be cancer-targeting.

In conclusion, CSCs contribute to resistance to conventional chemotherapy and radiation (22), and are believed to be the major culprits in cancer recurrence and metastasis (5). Present therapies that target rapidly dividing non-stem cell bulk populations in the tumor may produce rapid tumor shrinkage, but they are unlikely to produce long-term remissions unless the CSCs responsible for maintaining the disease are also targeted (62,63). Therefore, eradication of CSCs in the bulk tumor directly affects prognosis (64). In the present study, we proved that cantharidin and norcantharidin could repress the stemness of pancreatic cancer cells and strengthen the cytotoxicity of pharmacotherapeutics against pancreatic cancer, suggesting cantharidin and norcantharidin show promise as therapeutics against pancreatic cancer and may bring new light to the treatment of this aggressive neoplasm.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (nos. 81472296, 81101867, 81272542 and 81200369), the CSPAC-Celgene Foundation, the China International Medical Foundation (grant no. CIMF-F-H001-057), the Special Foundation of Clinical Medicine of Jiangsu Provincial Bureau of Science and Technology (grant no. BL2014039), the Scientific Research Project of Jiangsu Provincial Bureau of Traditional Chinese Medicine (grant no. L213236), the Medical Scientific Research Project of Jiangsu Provincial Bureau of Health (grant no. ZZ201206), the Special Foundation of Wu Jieping Medical Foundation for Clinical Scientific Research (grant nos. 320.6753.1225 and 320.6750.12242), the Science and Education for Health Foundation of Suzhou for Youth (grant nos. SWKQ1003 and SWKQ1011), the Science and Technology Project Foundation of Suzhou (grant nos. SYS201112, SYS2012137 and SYS201335), the Science and Technology Foundation of Suzhou Xiangcheng (grant nos. SZXC2012-70 and XI201451) and a Project founded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

References


